Summary
41.98 0.01(0.01%)07/03/2024
Surmodics, Inc. (SRDX)
Surmodics, Inc. (SRDX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.00 | 0.04 | -0.18 | 55.69 | 22.66 | 35.67 | 2.08 | 933.23 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 41.98 | |
| Open | 41.93 | |
| High | 42.00 | |
| Low | 41.91 | |
| Volume | 137,769 | |
| Change | 0.00 | |
| Change % | 0.00 | |
| Avg Volume (20 Days) | 288,230 | |
| Volume/Avg Volume (20 Days) Ratio | 0.48 | |
| 52 Week Range | 25.21 - 42.36 | |
| Price vs 52 Week High | -0.91% | |
| Price vs 52 Week Low | 66.50% | |
| Range | 0.11 | |
| Gap Up/Down | -0.05 | |
Fundamentals | ||
| Market Capitalization (Mln) | 599 | |
| EBIDTA | 27,201,000 | |
| PE Ratio | 32.9063 | |
| PEG Ratio | 3.8952 | |
| WallStreet Target Price | 58.25 | |
| Book Value | 8.6920 | |
| Earnings Per Share | 0.9600 | |
| EPS Estimate Current Quarter | -0.3200 | |
| EPS Estimate Next Quarter | -0.3200 | |
| EPS Estimate Current Year | -0.5500 | |
| EPS Estimate Next Year | -0.4800 | |
| Diluted EPS (TTM) | 0.9600 | |
| Revenues | ||
| Profit Marging | 0.0944 | |
| Operating Marging (TTM) | 0.0206 | |
| Return on asset (TTM) | 0.0661 | |
| Return on equity (TTM) | 0.1192 | |
| Revenue TTM | 142,963,008 | |
| Revenue per share TTM | 10.1470 | |
| Quarterly Revenue Growth (YOY) | 0.1750 | |
| Quarterly Earnings Growth (YOY) | 4.3580 | |
| Gross Profit (TTM) | 29,000,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 32.9063 | |
| Forward PE | 81.9672 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.1409 | |
| Revenue Enterprise Value | 2.7667 | |
| EBITDA Enterprise Value | 17.3305 | |
| Shares | ||
| Shares Outstanding | 14,260,000 | |
| Shares Float | 10,631,971 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.04 | |
| Insider (%) | 3.74 | |
| Institutions (%) | 91.42 | |
07/03 15:02 EST - prnewswire.com
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates Merger of Surmodics, Inc. - SRDX
NEW YORK , July 3, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Surmodics, Inc. (Nasdaq: SRDX ), relating to its proposed sale to GTCR LLC.
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates Merger of Surmodics, Inc. - SRDX
NEW YORK , July 3, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Surmodics, Inc. (Nasdaq: SRDX ), relating to its proposed sale to GTCR LLC.
06/11 11:41 EST - zacks.com
Surmodics (SRDX) Inks Group Purchasing Agreement With Premier
Surmodics (SRDX) inks the group purchasing agreement for its thrombectomy products with Premier.
Surmodics (SRDX) Inks Group Purchasing Agreement With Premier
Surmodics (SRDX) inks the group purchasing agreement for its thrombectomy products with Premier.
06/10 07:00 EST - businesswire.com
Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has been awarded a group purchasing agreement for thrombectomy products with Premier, Inc. Effective June 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Surmodics Pounce™ and Pounce™ Venous Thrombectomy Systems. “This is an exciting.
Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has been awarded a group purchasing agreement for thrombectomy products with Premier, Inc. Effective June 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Surmodics Pounce™ and Pounce™ Venous Thrombectomy Systems. “This is an exciting.
05/31 12:35 EST - zacks.com
Why Is SurModics (SRDX) Up 21.9% Since Last Earnings Report?
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?
Why Is SurModics (SRDX) Up 21.9% Since Last Earnings Report?
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?
05/31 12:31 EST - zacks.com
Surmodics (SRDX) Enters Deal to be Acquired by GTCR for $627M
Surmodics (SRDX) enters a definitive agreement to be acquired by renowned private equity company GTCR at an estimated total equity valuation of $627 million.
Surmodics (SRDX) Enters Deal to be Acquired by GTCR for $627M
Surmodics (SRDX) enters a definitive agreement to be acquired by renowned private equity company GTCR at an estimated total equity valuation of $627 million.
05/30 22:30 EST - accesswire.com
SURMODICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX
NEW ORLEANS, LA / ACCESSWIRE / May 30, 2024 / Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
SURMODICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX
NEW ORLEANS, LA / ACCESSWIRE / May 30, 2024 / Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
05/29 18:36 EST - prnewswire.com
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Surmodics, Inc.
NEW YORK , May 29, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Surmodics, Inc. (NASDAQ: SRDX) and its board of directors concerning the proposed acquisition of the company by GTCR. Stockholders will receive $43.00 for each share of Surmodics stock that they hold.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Surmodics, Inc.
NEW YORK , May 29, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Surmodics, Inc. (NASDAQ: SRDX) and its board of directors concerning the proposed acquisition of the company by GTCR. Stockholders will receive $43.00 for each share of Surmodics stock that they hold.
05/29 11:55 EST - investors.com
Surmodics Stock Rockets, But Merck Stock Little Moved, On Takeover Deals
Merck and Surmodics announced big takeover deals Wednesday, but Merck stock remained at a standstill as Surmodics stock rocketed.
Surmodics Stock Rockets, But Merck Stock Little Moved, On Takeover Deals
Merck and Surmodics announced big takeover deals Wednesday, but Merck stock remained at a standstill as Surmodics stock rocketed.
05/29 10:45 EST - prnewswire.com
Shareholder Alert: Ademi LLP investigates whether Surmodics, Inc. has obtained a Fair Price for its Public Shareholders
MILWAUKEE , May 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Surmodics (Nasdaq: SRDX) for possible breaches of fiduciary duty and other violations of law in its transaction with GTCR. Click here to learn how to join the https://www.ademilaw.com/case/surmodics-inc or call Guri Ademi toll-free at 866-264-3995.
Shareholder Alert: Ademi LLP investigates whether Surmodics, Inc. has obtained a Fair Price for its Public Shareholders
MILWAUKEE , May 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Surmodics (Nasdaq: SRDX) for possible breaches of fiduciary duty and other violations of law in its transaction with GTCR. Click here to learn how to join the https://www.ademilaw.com/case/surmodics-inc or call Guri Ademi toll-free at 866-264-3995.
05/29 08:16 EST - businesswire.com
SRDX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Surmodics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Surmodics, Inc. (NASDAQ: SRDX) to GTCR for $43.00 per share in cash is fair to Surmodics shareholders. Halper Sadeh encourages Surmodics shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Surmodics and its board o.
SRDX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Surmodics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Surmodics, Inc. (NASDAQ: SRDX) to GTCR for $43.00 per share in cash is fair to Surmodics shareholders. Halper Sadeh encourages Surmodics shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Surmodics and its board o.
05/29 07:00 EST - businesswire.com
Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it has entered into a definitive agreement to be acquired by GTCR, a leading private equity firm with a long track record of investment expertise across healthcare and healthcare technology. Under the terms of the agreement, affiliates of GTCR will acquire all outstanding shares of Surmodics. Surmodics shareholde.
Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it has entered into a definitive agreement to be acquired by GTCR, a leading private equity firm with a long track record of investment expertise across healthcare and healthcare technology. Under the terms of the agreement, affiliates of GTCR will acquire all outstanding shares of Surmodics. Surmodics shareholde.
05/20 00:00 EST - https://www.zacks.com
Here's Why You Should Hold Surmodics (SRDX) Stock for Now
Surmodics, Inc. (SRDX Quick QuoteSRDX - Free Report) is well-poised for growth in the coming quarters, courtesy of its solid prospects in the thrombectomy business over the past few months. The optimism led by a solid second-quarter performance and consistent efforts to boost research and development (R&D) are expected to contribute further. Yet, concerns regarding regulatory headwinds and reliance on third parties persist.So far this year, this current Zacks Rank #3 (Hold) company has declined 4.8% against the industry’s 4.2% rise and the S&P 500’s 11.6% growth.The renowned medical device and in-vitro diagnostics technology provider has a market capitalization of $493.68 million. Surmodics projects 97.2% growth for fiscal 2025 and expects to maintain its strong performance. SRDX’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average earnings surprise being 165.93%. Image Source: Zacks Investment ResearchLet’s delve deeper.Consistent Efforts to Boost R&D: Surmodics’ solid efforts to improve its R&D stature have been a key growth driver, which raises our optimism. The company’s pipeline of vascular intervention medical device products under development and recently commercialized include primary platforms like DCBs, Mechanical thrombectomy devices and Radial access devices. In addition to these primary platforms, Surmodics’ device manufacturing operations include Specialty catheters.In the second quarter, Surmodics’ R&D expenses were 27.6% of total revenues. Medical Device R&D and other revenues increased 1.4% in the fiscal second quarter compared with the prior-year quarter, driven by increased volume of performance coating services.Thrombectomy Prospects Bright: Surmodics’ aim to leverage its proprietary Pounce thrombectomy platform technology to develop products raises our optimism. The company announced the completion of limited market evaluation and commercial launch of two new mechanical thrombectomy systems for the peripheral venous and arterial vasculatures, the Pounce Venous Thrombectomy System and the Pounce LP (Low Profile) Thrombectomy System during the fiscal second quarter.In January, Surmodics announced the successful early clinical use of the Pounce LP Thrombectomy System. Strong Q2 Results: Surmodics registered a solid uptick in the overall top and bottom lines in the second quarter. Product sales growth in the Medical Device segment was driven primarily by the fulfillment of the initial stocking order for the SurVeil DCB from Abbott and continued sales growth from the Pounce thrombectomy device platform.DownsidesRegulatory Headwinds: Surmodics’ facilities and procedures are subject to periodic inspections by the FDA to determine compliance with the latter’s requirements. On account of non-compliance with applicable laws or regulations, the FDA could ban such medical devices. Any adverse regulatory action can potentially hurt Surmodics' business practices and operations.Reliance on Third Parties: A principal element of Surmodics’ business strategy is to enter into licensing arrangements with medical devices and other companies that manufacture products incorporating its technologies. The company’s revenues from such arrangements depend upon its ability or its licensees’ ability to successfully develop, obtain regulatory approval for manufacture (if applicable), and market and sell products incorporating Surmodics’ technologies. Any failure to meet these requirements could have an adverse effect on its business.Estimate TrendSurmodics is witnessing a positive estimate revision trend for fiscal 2024. In the past 30 days, the Zacks Consensus Estimate for its loss per share has narrowed from 90 cents to 72 cents.The consensus estimate for the company’s third-quarter fiscal revenues is pegged at $30.3 million, suggesting a 42.2% decline from the year-ago reported number. Loss for the period is estimated to widen 157.7% year over year to 30 cents per share.Surmodics, Inc. Price Surmodics, Inc. price | Surmodics, Inc. QuoteKey PicksSome better-ranked stocks in the broader medical space are DaVita Inc. (DVA Quick QuoteDVA - Free Report) , Align Technology (ALGN Quick QuoteALGN - Free Report) and Medpace (MEDP Quick QuoteMEDP - Free Report) .DaVita, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 13.6%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 29.4%. DaVita’s shares have risen 33.4% compared with the industry’s 11.2% growth year to date.Medpace, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 17.9%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.8%.Medpace’s shares have risen 28.3% year to date compared with the industry’s 4.9% growth.Align Technology, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 6.9%. Its earnings surpassed estimates in three of the trailing four quarters and missed the same in one quarter, delivering an average surprise of 5.9%.ALGN’s shares have declined 0.9% year to date against the industry’s 2.8% growth. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>
Here's Why You Should Hold Surmodics (SRDX) Stock for Now
Surmodics, Inc. (SRDX Quick QuoteSRDX - Free Report) is well-poised for growth in the coming quarters, courtesy of its solid prospects in the thrombectomy business over the past few months. The optimism led by a solid second-quarter performance and consistent efforts to boost research and development (R&D) are expected to contribute further. Yet, concerns regarding regulatory headwinds and reliance on third parties persist.So far this year, this current Zacks Rank #3 (Hold) company has declined 4.8% against the industry’s 4.2% rise and the S&P 500’s 11.6% growth.The renowned medical device and in-vitro diagnostics technology provider has a market capitalization of $493.68 million. Surmodics projects 97.2% growth for fiscal 2025 and expects to maintain its strong performance. SRDX’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average earnings surprise being 165.93%. Image Source: Zacks Investment ResearchLet’s delve deeper.Consistent Efforts to Boost R&D: Surmodics’ solid efforts to improve its R&D stature have been a key growth driver, which raises our optimism. The company’s pipeline of vascular intervention medical device products under development and recently commercialized include primary platforms like DCBs, Mechanical thrombectomy devices and Radial access devices. In addition to these primary platforms, Surmodics’ device manufacturing operations include Specialty catheters.In the second quarter, Surmodics’ R&D expenses were 27.6% of total revenues. Medical Device R&D and other revenues increased 1.4% in the fiscal second quarter compared with the prior-year quarter, driven by increased volume of performance coating services.Thrombectomy Prospects Bright: Surmodics’ aim to leverage its proprietary Pounce thrombectomy platform technology to develop products raises our optimism. The company announced the completion of limited market evaluation and commercial launch of two new mechanical thrombectomy systems for the peripheral venous and arterial vasculatures, the Pounce Venous Thrombectomy System and the Pounce LP (Low Profile) Thrombectomy System during the fiscal second quarter.In January, Surmodics announced the successful early clinical use of the Pounce LP Thrombectomy System. Strong Q2 Results: Surmodics registered a solid uptick in the overall top and bottom lines in the second quarter. Product sales growth in the Medical Device segment was driven primarily by the fulfillment of the initial stocking order for the SurVeil DCB from Abbott and continued sales growth from the Pounce thrombectomy device platform.DownsidesRegulatory Headwinds: Surmodics’ facilities and procedures are subject to periodic inspections by the FDA to determine compliance with the latter’s requirements. On account of non-compliance with applicable laws or regulations, the FDA could ban such medical devices. Any adverse regulatory action can potentially hurt Surmodics' business practices and operations.Reliance on Third Parties: A principal element of Surmodics’ business strategy is to enter into licensing arrangements with medical devices and other companies that manufacture products incorporating its technologies. The company’s revenues from such arrangements depend upon its ability or its licensees’ ability to successfully develop, obtain regulatory approval for manufacture (if applicable), and market and sell products incorporating Surmodics’ technologies. Any failure to meet these requirements could have an adverse effect on its business.Estimate TrendSurmodics is witnessing a positive estimate revision trend for fiscal 2024. In the past 30 days, the Zacks Consensus Estimate for its loss per share has narrowed from 90 cents to 72 cents.The consensus estimate for the company’s third-quarter fiscal revenues is pegged at $30.3 million, suggesting a 42.2% decline from the year-ago reported number. Loss for the period is estimated to widen 157.7% year over year to 30 cents per share.Surmodics, Inc. Price Surmodics, Inc. price | Surmodics, Inc. QuoteKey PicksSome better-ranked stocks in the broader medical space are DaVita Inc. (DVA Quick QuoteDVA - Free Report) , Align Technology (ALGN Quick QuoteALGN - Free Report) and Medpace (MEDP Quick QuoteMEDP - Free Report) .DaVita, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 13.6%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 29.4%. DaVita’s shares have risen 33.4% compared with the industry’s 11.2% growth year to date.Medpace, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 17.9%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.8%.Medpace’s shares have risen 28.3% year to date compared with the industry’s 4.9% growth.Align Technology, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 6.9%. Its earnings surpassed estimates in three of the trailing four quarters and missed the same in one quarter, delivering an average surprise of 5.9%.ALGN’s shares have declined 0.9% year to date against the industry’s 2.8% growth. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>
05/03 14:16 EST - zacks.com
Surmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up
Surmodics (SRDX) fiscal second-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.
Surmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up
Surmodics (SRDX) fiscal second-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.
05/01 10:35 EST - zacks.com
SurModics (SRDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
SurModics (SRDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
05/01 09:31 EST - zacks.com
SurModics (SRDX) Q2 Earnings and Revenues Top Estimates
SurModics (SRDX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.36 per share. This compares to loss of $0.40 per share a year ago.
SurModics (SRDX) Q2 Earnings and Revenues Top Estimates
SurModics (SRDX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.36 per share. This compares to loss of $0.40 per share a year ago.
05/01 07:00 EST - businesswire.com
Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #PressRelease--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2024, and updated financial guidance for its fiscal year ending September 30, 2024. Second Quarter Fiscal 2024 Financial Summary Total Revenue of $32.0 million, an increase of 18% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon (“DCB”).
Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #PressRelease--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2024, and updated financial guidance for its fiscal year ending September 30, 2024. Second Quarter Fiscal 2024 Financial Summary Total Revenue of $32.0 million, an increase of 18% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon (“DCB”).
04/19 07:00 EST - businesswire.com
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #EarningsCall--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, May 1. Management will host a live webcast and conference call at 7:00 a.m. CT (8:00 a.m. ET) on Wednesday, May 1, to discuss the second quarter fiscal 2024 financial results and accomplishments and.
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #EarningsCall--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, May 1. Management will host a live webcast and conference call at 7:00 a.m. CT (8:00 a.m. ET) on Wednesday, May 1, to discuss the second quarter fiscal 2024 financial results and accomplishments and.
04/17 11:06 EST - zacks.com
Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/09 07:16 EST - zacks.com
New Strong Buy Stocks for April 9th
SRDX, X, TELNY, INSP and MTAL have been added to the Zacks Rank #1 (Strong Buy) List on April 9, 2023.
New Strong Buy Stocks for April 9th
SRDX, X, TELNY, INSP and MTAL have been added to the Zacks Rank #1 (Strong Buy) List on April 9, 2023.